Despite advancements in the cloning of the human genome, biomedical innovations at patient level are rare events. Translational medicine is, however, a burgeoning science that shows potential to reverse the trend. This textbook provides a survey of translational medicine, emphasising its emerging scientific backbone, its strengths and weaknesses. It explores all aspects of preclinical and clinical issues relevant to the success of translational pharmaceutical or medical device or diagnostic innovations, including target risk assessment, biomarker evaluation, and predictivity grading for both efficacy and toxicity; early human trial designs, adequate to guide stop or go decisions on the grounds of biomarker panels; and biostatistical methods to analyze multiple readout situations and quantify risk projections. Translational Science in Medicine provides guidance to design profiling strategies for new approaches to the field. By generating dialogue about translational science Wehling explores the implications of this field on the future of patient care.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Professor Mark Wehling is an internist, cardiologist, and full professor of clinical pharmacology at the University of Heidelberg, Germany. He has authored more than 200 scientific publications and several books and has been recipient of the Heisenberg Scholarship from Deutsche Forschungsgemeinschaft. After working as Director of Discovery Medicine at AstraZeneca, he returned to his academic position in 2007. In his return to academia, his aim is to further translational medicine by aligning academic and private activities to support biomedical innovation. His main tools are connecting distant players in the translational process; bridging gaps between preclinical and clinical stages; assembling, developing, and profiling biomarkers with particular assessment of their predictive value; and developing smart translational plans to reliably and swiftly promote translatable projects.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Webbooks, Wigtown, Wigtown, Royaume-Uni
Hard Cover. Etat : Good. No Jacket. First Edition. From an academic library with the usual stamps etc. This item is heavy and will attract postal surcharges. N° de réf. du vendeur B00005575
Quantité disponible : 1 disponible(s)
Vendeur : Webbooks, Wigtown, Wigtown, Royaume-Uni
Hard Cover. Etat : Good. No Jacket. First Edition. From an academic library with the usual stamps etc. This item is heavy and will attract postal surcharges. N° de réf. du vendeur B00005576
Quantité disponible : 1 disponible(s)
Vendeur : Webbooks, Wigtown, Wigtown, Royaume-Uni
Hard Cover. Etat : Good. No Jacket. First Edition. From an academic library with the usual stamps and labels. This item is heavy and will attract postal surcharges. A00014099. N° de réf. du vendeur A00014099
Quantité disponible : 1 disponible(s)
Vendeur : Labyrinth Books, Princeton, NJ, Etats-Unis
Etat : Very Good. N° de réf. du vendeur 173558
Quantité disponible : 1 disponible(s)
Vendeur : Llibreria Hispano Americana, Barcelona, B, Espagne
Etat : Nuevo. N° de réf. du vendeur 5.10
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Hardcover. Etat : Sehr gut. Gebraucht - Sehr gut Sg - leichte Beschädigungen oder Verschmutzungen, ungelesenes Mängelexemplar, gestempelt - Despite advancements in the cloning of the human genome, biomedical innovations at patient level are rare events. Translational medicine is, however, a burgeoning science that shows potential to reverse the trend. This textbook provides a survey of translational medicine, emphasising its emerging scientific backbone, its strengths and weaknesses. It explores all aspects of preclinical and clinical issues relevant to the success of translational pharmaceutical or medical device or diagnostic innovations, including target risk assessment, biomarker evaluation, and predictivity grading for both efficacy and toxicity; early human trial designs, adequate to guide stop or go decisions on the grounds of biomarker panels; and biostatistical methods to analyze multiple readout situations and quantify risk projections. Translational Science in Medicine provides guidance to design profiling strategies for new approaches to the field. By generating dialogue about translational science Wehling explores the implications of this field on the future of patient care. N° de réf. du vendeur INF1000770371
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Hardcover. Etat : Neu. Neu Neu - Neuware, Importqualität, auf Lager - Despite advancements in the cloning of the human genome, biomedical innovations at patient level are rare events. Translational medicine is, however, a burgeoning science that shows potential to reverse the trend. This textbook provides a survey of translational medicine, emphasising its emerging scientific backbone, its strengths and weaknesses. It explores all aspects of preclinical and clinical issues relevant to the success of translational pharmaceutical or medical device or diagnostic innovations, including target risk assessment, biomarker evaluation, and predictivity grading for both efficacy and toxicity; early human trial designs, adequate to guide stop or go decisions on the grounds of biomarker panels; and biostatistical methods to analyze multiple readout situations and quantify risk projections. Translational Science in Medicine provides guidance to design profiling strategies for new approaches to the field. By generating dialogue about translational science Wehling explores the implications of this field on the future of patient care. N° de réf. du vendeur INF1000770926
Quantité disponible : 1 disponible(s)
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
Hardcover. Etat : Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book. N° de réf. du vendeur ERICA82905218886976
Quantité disponible : 1 disponible(s)